As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients
Published in: British Journal of Haematology
The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum-based salvage chemotherapy at the University Medical Center Groningen. In total, 124 plasma samples were analysed using low-coverage whole-genome sequencing to detect copy number alterations (CNAs) and targeted sequencing with a 115-gene panel for single- and multi-nucleotide variants (SNVs/MNVs). The complete response rate at the end...
Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma
Published in: European Journal of Cancer
BACKGROUND: Patients with limited-stage primary testicular lymphoma (PTL) typically receive a multimodal regimen, including 6 cycles of R-CHOP, despite limited evidence. In low-risk diffuse large B-cell lymphoma, de-escalation to 4 R-CHOP cycles has proven non-inferior. It remains unclear whether similar de-escalation is feasible in PTL. METHODS: Patients aged ≥ 18 years with Ann Arbor stage I-II PTL diagnosed between 2014 and 2021 were identified in the Netherlands Cancer Registry. Patients receiving ≥ 3 R-CHOP cycles were included. Outcomes were 5-year progression-free survival (PFS), overall survival (OS), and cumulative incidence function...
Diana Al-Sarayfi, Johanna A A Bult, Ruben A L de Groen, Fleur A de Groot, Joost S P Vermaat, Djamilla Issa,
Arjan Diepstra,
Gerwin Huls,
Mar Bellido,
Wouter Plattel,
Mirian Brink,
Marcel Nijland
Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin Lymphoma
Published in: Blood Advances
Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial
Published in: HemaSphere
Wouter J Plattel,
Sophie Teesink,
Lydia Visser, Conrad-Amadeus Voltin, Helen Kaul, Hans A Schlößer,
Bart-Jan Kroesen, Carsten Kobe, Bastian von Tresckow, Peter Borchmann,
Arjan Diepstra, Paul J Bröckelmann
Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
Published in: HemaSphere
Carsten Kobe, Philippe Armand, Sven Borchmann, Graham P Collins, Anne-Segolene Cottereau, Justin Ferdinandus, Alex F Herrera, Davide Rossi,
Wouter J Plattel, Sally F Barrington, Martin Hutchings
